First Report Managed Care

JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

First Report Managed Care Newsletter Brand/Meeting More

JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

Medication adherence is one of the clearest indicators of whether plans can successfully translate insight into action, but it is too often approached in a transactional way: identify a refill gap, send a reminder, and encourage a refill. However, adherence is not fundamentally a reminder problem. It’s a behavior problem. People do not become adherent simply because they receive a single text message reminder or outreach call.

AMP_PAGE_VIEWPending Maximum Storage Duration: SessionType: HTML Local Storage AMP_remote_config_090786228dPending Maximum Storage Duration: PersistentType: HTML Local Storage AMP_SR_START_090786228d_1780812854728Pending Maximum Storage Duration: PersistentType: HTML Local Storage AMP_SR_START_090786228d_1780812929532Pending Maximum Storage Duration: PersistentType: HTML Local Storage AMP_URL_INFOPending Maximum Storage Duration: SessionType: HTML Local Storage EXP_090786228dPending Maximum...

JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

Joe DePinto: My name is Joe DePinto. I’m the Head of Cell, Gene, and Advanced Therapies at McKesson. I lead McKesson’s cell, gene, and advanced therapies vertical, called InspiroGene. We help our clients navigate the value chain involved in delivering complex therapeutic interventions such as cell, gene, and advanced therapies. Our clients include biopharmaceutical companies, sites of care, and other stakeholders, including payers.

Capitol Hill has started to quiet down as members of Congress turn their attention toward reelection campaigns. While this means the pace of change in policy is less intense than the beginning of the year, with the enactment of the Consolidated Appropriations Act and its pharmacy benefit manager (PBM) reform provisions, there are still a couple of things managed care professionals should pay attention to this summer.

Key Takeaways: Omalizumab is associated with lower health care resource utilization (HCRU) for patients with food allergies and comorbid asthma and food allergies. Emergency department (ED) visits, hospitalizations, and outpatient visits substantially decreased after omalizumab introduction. Omalizumab is associated with lower care costs relating to food allergies and asthma. ED and outpatient condition-based costs were greatly reduced.